Join to View Full Profile
480 Arsenal StWatertown, MA 02472
Phone+1 617-455-2296
Dr. Modur is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Vijay Modur, based in Watertown, MA, is a specialist in pathology with subspecialties in blood banking & transfusion medicine, chemical pathology, molecular genetics, and clinical pathology. He completed his residency in anatomic and clinical pathology at the Washington University/B-JH/SLCH Consortium in 2002 after graduating from the Karnataka Institute of Medical Science in 1990. His recent publications include studies on novel therapeutic agents and methodologies, some focusing on conditions like familial adenomatous polyposis, ADPKD, and Fabry disease, contributing to journals such as the Journal of Molecular Medicine, American Journal of Kidney Diseases, and Molecular Genetics and Metabolism. His published works have garnered citations, indicating engagement with the research community.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 1997 - 2002
Karnataka Institute of Medical ScienceClass of 1990
Certifications & Licensure
MO State Medical License 2010 - 2026
American Board of Pathology Clinical Pathology
Publications & Presentations
PubMed
- 9 citationsVenglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase...Ronald T Gansevoort, Ali Hariri, Pascal Minini, Curie Ahn, Arlene B Chapman
American Journal of Kidney Diseases. 2023-05-01 - 3 citationsNovel read through agent: ZKN-0013 demonstrates efficacy in APCmodel of familial adenomatous polyposis.Martin R Graf, Shruti Apte, Esteban Terzo, Simran Padhye, Shuhao Shi
Journal of Molecular Medicine. 2023-04-01 - 21 citationsVenglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 stud...Patrick B Deegan, Ozlem Goker-Alpan, Tarekegn Geberhiwot, Robert J Hopkin, Elena Lukina
Molecular Genetics and Metabolism. 2023-02-01
Press Mentions
BPGbio Receives FDA Rare Pediatric Disease Designation for Its Investigational Treatment for Epidermolysis BullosaOctober 31st, 2024- ELX-02 Lowers Sweat Chloride in Patients with G542X Mutation, Trials FindNovember 19th, 2021
- Eloxx Pharmaceuticals Appoints Chief Medical OfficerSeptember 8th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
